Canton Hathaway LLC increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,007 shares of the medical research company’s stock after acquiring an additional 626 shares during the period. Amgen comprises 1.3% of Canton Hathaway LLC’s holdings, making the stock its 8th largest position. Canton Hathaway LLC’s holdings in Amgen were worth $2,323,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. OmniStar Financial Group Inc. grew its holdings in Amgen by 16.6% in the third quarter. OmniStar Financial Group Inc. now owns 12,969 shares of the medical research company’s stock valued at $2,510,000 after purchasing an additional 1,851 shares during the period. Rothschild Investment Corp IL grew its holdings in Amgen by 4.5% in the third quarter. Rothschild Investment Corp IL now owns 71,963 shares of the medical research company’s stock valued at $13,926,000 after purchasing an additional 3,083 shares during the period. Nottingham Advisors Inc. acquired a new stake in Amgen in the third quarter valued at approximately $216,000. Successful Portfolios LLC grew its holdings in Amgen by 4.8% in the third quarter. Successful Portfolios LLC now owns 1,775 shares of the medical research company’s stock valued at $343,000 after purchasing an additional 81 shares during the period. Finally, Verity & Verity LLC grew its holdings in Amgen by 4.2% in the third quarter. Verity & Verity LLC now owns 28,717 shares of the medical research company’s stock valued at $5,648,000 after purchasing an additional 1,155 shares during the period. 76.24% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total value of $413,400.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at $3,376,651.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Cynthia M. Patton sold 13,426 shares of Amgen stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $208.07, for a total value of $2,793,547.82. Following the completion of the sale, the senior vice president now directly owns 32,648 shares in the company, valued at $6,793,069.36. The disclosure for this sale can be found here. Insiders sold 17,851 shares of company stock worth $3,671,900 over the last ninety days. Corporate insiders own 0.25% of the company’s stock.
Several brokerages have commented on AMGN. Morgan Stanley dropped their price objective on Amgen from $211.00 to $207.00 and set an “overweight” rating on the stock in a report on Monday, July 15th. Goldman Sachs Group set a $243.00 price objective on Amgen and gave the company a “buy” rating in a report on Monday, September 30th. BMO Capital Markets set a $240.00 price objective on Amgen and gave the company a “buy” rating in a report on Monday, September 30th. Cowen set a $231.00 price objective on Amgen and gave the company a “buy” rating in a report on Sunday, September 29th. Finally, William Blair reissued a “hold” rating on shares of Amgen in a report on Friday, August 30th. Eleven analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Amgen presently has an average rating of “Hold” and a consensus target price of $217.41.
Shares of NASDAQ:AMGN traded up $2.12 during trading on Friday, reaching $200.80. The stock had a trading volume of 2,472,238 shares, compared to its average volume of 2,971,894. The company has a debt-to-equity ratio of 2.58, a quick ratio of 2.60 and a current ratio of 2.89. The business has a fifty day moving average price of $199.57 and a 200-day moving average price of $186.20. The stock has a market cap of $117.59 billion, a PE ratio of 13.94, a PEG ratio of 2.55 and a beta of 1.11. Amgen, Inc. has a 1-year low of $166.30 and a 1-year high of $211.90.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business’s revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.83 earnings per share. Sell-side analysts expect that Amgen, Inc. will post 14.31 earnings per share for the current year.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Equity Income
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.